US 12,280,055 B2
Combination therapies
Jacob Haling, San Diego, CA (US); John Michael Ketcham, Carlsbad, CA (US); and Shilpi Khare, San Diego, CA (US)
Assigned to MIRATI THERAPEUTICS, INC., Princeton, NJ (US)
Filed by Mirati Therapeutics, Inc., San Diego, CA (US)
Filed on May 24, 2022, as Appl. No. 17/752,609.
Claims priority of provisional application 63/329,056, filed on Apr. 8, 2022.
Claims priority of provisional application 63/194,140, filed on May 27, 2021.
Prior Publication US 2022/0395507 A1, Dec. 15, 2022
Int. Cl. A61K 31/519 (2006.01); A61K 31/502 (2006.01); A61K 31/5025 (2006.01); A61K 31/506 (2006.01); A61K 31/5377 (2006.01); A61K 31/5383 (2006.01); A61P 11/00 (2006.01); A61P 35/00 (2006.01)
CPC A61K 31/519 (2013.01) [A61K 31/502 (2013.01); A61K 31/5025 (2013.01); A61K 31/506 (2013.01); A61K 31/5377 (2013.01); A61K 31/5383 (2013.01); A61P 11/00 (2018.01); A61P 35/00 (2018.01)] 34 Claims
 
1. A method of treating cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a combination of the KRas G12C inhibitor adagrasib:

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof, and a SOS1 inhibitor, wherein the SOS1 inhibitor is

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof; wherein the cancer is a KRas G12C-associated cancer selected from the group consisting of lung cancer; gastrointestinal cancer; genitourinary tract cancer; liver cancer; biliary tract cancer; bone cancer; nervous system cancer; gynecological cancer; hematologic cancer; skin cancer; and adrenal glands cancer.